Key facts
- Enduro’s last known valuation is $36.0M (Feb 2025).
- It has raised $16.1M; the latest was Later Stage VC ($12.5M) in Feb 2025.
- Notable investors include European Innovation Council, Supernova Invest, BioInnovation Institute, European Innovation Council (Belgium), Green Development and Demonstration Program — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Enduro
- ·The full record, as it builds
Funding rounds
No funding rounds for Enduro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enduro
Developer of a synthetic addiction technology designed to solve the challenge of microbial productivity in biomanufacturing. The company offers its patented Sense technology, which boosts yields, reduces costs, waste and eases the production of complex or cellular inhibitors when strain instability is overcome, enabling industries in biochemicals, alternative proteins, and pharmaceuticals to achieve scalable, sustainable production with improved efficiency.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2016
- Employees
- 38
- Website
- enduro.bio/
- Ownership
- Privately Held (backing)
Enduro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enduro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enduro in its N-PORT filings yet. We sweep new filings monthly.